In July 2025, Janssen Research & Development LLC conducted a study is to evaluate the efficacy of icotrokinra compared to ...

Patients with psoriatic arthritis with a family history of psoriatic disease are diagnosed with psoriasis and psoriatic ...

Sun Pharma’s INSPIRE-1 and INSPIRE-2 studies met their primary endpoint at Week 24, with Ilumya 100 mg demonstrating superior ...

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

While IL-17 blocking agents are linked to an increased risk for candidiasis, bimekizumab, which blocks two proteins ...

Early intervention in psoriatic arthritis (PsA) is disease-modifying, and delays in diagnosis, even by 6 months, can reduce ...

Discover effective treatments for psoriatic arthritis, with expert tips on managing symptoms, reducing inflammation, and improving joint health for a better quality of life.

Submission is supported by 24-week results from the Phase 3b APEX study in adults with active psoriatic arthritis treated with TREMFYA.

“This study suggests that subclinical synovitis is more prevalent among patients with psoriasis without musculoskeletal involvement than healthy controls, suggesting that imaging may help identify ...

B oth men and women with psoriasis are equally at risk for developing psoriatic arthritis (PsA)-a chronic inflammatory ...

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.